Combining Biomarkers for Immunotherapy
- PMID: 30377168
- DOI: 10.1158/2159-8290.CD-NB2018-143
Combining Biomarkers for Immunotherapy
Abstract
A biomarker analysis involving the largest dataset of its kind finds that tumor mutational burden and T cell-inflamed gene expression profile can independently predict a patient's response to pembrolizumab. However, joint consideration of both biomarkers offers the greatest clinical utility and identifies patterns of underlying, targetable biology.
©2018 American Association for Cancer Research.
Comment on
-
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.Science. 2018 Oct 12;362(6411):eaar3593. doi: 10.1126/science.aar3593. Science. 2018. PMID: 30309915 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
